Clinical drug development is moving away from traditional approaches that rely on rare disease patients to travel long distances to clinical sites and toward a more patient-focused paradigm, one that highlights virtual and decentralized clinical trials (DCT). By bringing trials directly to patients instead of requiring patients to travel to sites, we can alleviate a primary burden of clinical trial participation and democratize clinical trial access. In this white paper, you’ll learn the following key points:
- How the new research model can increase access to trials, allowing us to bring new therapies to rare disease patients faster.
- How practical strategies for easing patient participation burdens will aid in transitioning from traditional site-based paradigms to more patient-focused virtual or DCT models.
- What considerations must be made to select technology that seamlessly integrates clinical trials into patients’ lives.

You may also be interested in:

PRA’s Mobile Health Platform
PRA’s Mobile Health Platform (MHP) engages with patients wherever they are. Our app-based platform allows us to do everything that’s possible in a…

Decentralized Clinical Trials: The Call for a New Paradigm
The existing framework around modern clinical trials is antiquated and inefficient. The foundations for clinical development date back to the 1938 US…

COVID-19 Kicks Healthcare Technology Adaptation into High Gear
From telemedicine to decentralized clinical trials to artificial intelligence and beyond, the COVID-19 crisis has kicked the use of technology in the…